Modeling did not incorporate the impact of novel treatments (e.g., immunotherapy for high microsatellite instability, mismatch repair deficiency, or high tumor mutational burden cancers), or the addition of biological agents (e.g., panitumumab, cetuximab, and bevacizumab) or more nuanced prognostic factors (e.g., the presence of a BRAF mutation or sidedness of the primary tumor). This evidence concerns the gene BRAF and cancer.